Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial

BACKGROUND - Cabazitaxel significantly improves overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) progressing during or after docetaxel, but is associated with a higher rate of grade ≥3 neutropenia compared with docetaxel.

We thus examined the relationship between cabazitaxel-induced grade ≥3 neutropenia, baseline neutrophil-lymphocyte ratio (NLR) and treatment outcomes.

METHODS - Data from the experimental arm of the TROPIC phase 3 trial which randomly assigned men with mCRPC to cabazitaxel or mitoxantrone every 3 weeks, both combined with daily prednisone, were analysed. The influence on OS (primary end-point) and progression-free survival (PFS) of at least one episode of grade ≥3 neutropenia during cabazitaxel therapy was investigated using Cox regression models, adjusted for pain at baseline. The relationships with prostate-specific antigen (PSA) responses during cabazitaxel therapy and baseline NLR were also analysed.

FINDINGS - The occurrence of grade ≥3 neutropenia during cabazitaxel therapy was associated with a prolonged OS (median 16. 3 versus 14. 0 months, hazard ratio (HR) [95% confidence interval] = 0. 65 [0. 43-0. 97], p = 0. 035), a twice longer PFS (median 5. 3 versus 2. 6 months, HR = 0. 56 [0. 40-0. 79], p = 0. 001) and a higher confirmed PSA response ≥50% (49. 8% versus 24. 4%, p = 0. 005), as compared with patients who did not develop grade ≥3 neutropenia. Grade ≥3 neutropenia was more common in case of NLR <3 as compared with NLR ≥3 at baseline (88. 8% versus 75. 3%, p = 0. 002). Combining low NLR at baseline and grade ≥3 neutropenia during therapy was associated with the longest OS (median 19. 2 months) while high NLR at baseline and no grade ≥3 neutropenia was associated with a poor OS (median 12. 9 months, HR 0. 46 [0. 28-0. 76], p = 0. 002). In the subgroup of neutropenic patients the median OS was 19. 7 months in those treated with granulocyte colony-stimulating factor (G-CSF) and 16 months on those without G-CSF support.

INTERPRETATIONS - This post-hoc analysis of TROPIC suggests that the occurrence of grade ≥3 neutropenia with cabazitaxel is associated with improved OS and PFS. Patients with a low NLR at baseline were more likely to develop grade ≥3 neutropenia during cabazitaxel therapy and showed the longest OS. High NLR at baseline and no grade ≥3 neutropenia during therapy was associated with poor outcomes which may suggest insufficient drug exposure or a limited impact on the tumour-associated immune response. Primary or secondary prophylactic use of G-CSF had no adverse impact for outcome. If prospectively confirmed, these results would justify maintaining the intended cabazitaxel dose of 25 mg/m(2) whenever possible.

European journal of cancer (Oxford, England : 1990). 2016 Jan 29 [Epub ahead of print]

Alexander Meisel, Stefanie von Felten, Deborah R Vogt, Heike Liewen, Ronald de Wit, Johann de Bono, Oliver Sartor, Frank Stenner-Liewen

Department of Oncology, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland; Department of Internal Medicine, Stadtspital Waid, Tièchestrasse 99, 8037 Zurich, Switzerland. , Clinical Trial Unit, CTU, University Hospital of Basel, Schanzenstrasse 55, 4031 Basel, Switzerland. , Clinical Trial Unit, CTU, University Hospital of Basel, Schanzenstrasse 55, 4031 Basel, Switzerland. , Department of Oncology, University Hospital of Basel, Petersgraben 4, 4031 Basel, Switzerland. , Erasmus MC, and ErasmusMC Cancer Institute, PO Box 5201, 3008 AE Rotterdam, The Netherlands. , Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5, UK. , Department of Medicine & Urology, Tulane Cancer Center, 1430 Tulane Avenue, SL-42, New Orleans, 70112 LA, USA. , Department of Oncology, University Hospital of Basel, Petersgraben 4, 4031 Basel, Switzerland.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe